Norwegian HTA for targeted deep sequencing panel

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method.”

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

In December of 2018, the completed mini method assessment for targeted deep sequencing panel for patients with different types of hematological neoplasia was released.

The following conclusions were provided:

• The good level of efficacy was shown by the method in comparison with other established methods (E.g., sanger sequencing):
  • More precise diagnostics
  • More targeted/personalized treatment
  • Opportunity to follow patient response to treatment to optimize the way of treatment
  • Opportunity for targeted treatment (E.g., IDH inhibitors in the future)
• In addition, the method should be used to follow national and international guidelines in accordance with the diagnosis
• The method was determined as safe (does not cause significant risk for patients/personnel)
• The method should be introduced as part of the clinical routine in the hospital

See the main results of the assessments in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.